Analytical Data
-
基因名
GPR30
- Application
-
别名
GPER1; CEPR; CMKRL2; DRY12; GPER; GPR30; G-protein coupled estrogen receptor 1; Chemoattractant receptor-like 2; Flow-induced endothelial G-protein coupled receptor 1; FEG-1; G protein-coupled estrogen receptor 1; G-protein coupled receptor 30
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q99527
-
表达区间
1-375aa
-
氨基酸序列
MDVTSQARGVGLEMYPGTAQPAAPNTTSPELNLSHPLLGTALANGTGELSEHQQYVIGLFLSCLYTIFLFPIGFVGNILILVVNISFREKMTIPDLYFINLAVADLILVADSLIEVFNLHERYYDIAVLCTFMSLFLQVNMYSSVFFLTWMSFDRYIALARAMRCSLFRTKHHARLSCGLIWMASVSATLVPFTAVHLQHTDEACFCFADVREVQWLEVTLGFIVPFAIIGLCYSLIVRVLVRAHRHRGLRPRRQKALRMILAVVLVFFVCWLPENVFISVHLLQRTQPGAAPCKQSFRHAHPLTGHIVNLAAFSNSCLNPLIYSFLGETFRDKLRLYIEQKTNLPALNRFCHAALKAVIPDSTEQSDVRFSSAV
-
分子量
68.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPR30, also known as G protein-coupled receptor 30, is an estrogen receptor that has garnered significant attention in recent years due to its role in mediating estrogen's non-genomic effects. Unlike the traditional estrogen receptors (ERα and ERβ), GPR30 is primarily associated with rapid signaling pathways, influencing a variety of physiological processes such as cell proliferation, differentiation, and apoptosis. The discovery of GPR30 highlighted the complexity of estrogen signaling, suggesting that estrogen may exert its effects through multiple pathways. Research has indicated that GPR30 is involved in a range of conditions, including cardiovascular diseases, cancer, and neurological disorders, thus positioning it as a potential therapeutic target. Recent studies have focused on the development of recombinant GPR30 proteins to explore their structure-function relationships, signaling mechanisms, and interactions with ligands. These efforts aim to elucidate how GPR30 contributes to estrogen signaling and to identify novel strategies for modulating its activity in various diseases. Understanding GPR30's role at a molecular level could open new avenues for targeted therapies, providing insights into the regulation of estrogen-related biological processes and offering potential interventions for estrogen-dependent pathologies.
